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Abstract
Background: The number of prosthesis brands used for hip replacement has increased rapidly, but there is little evidence
on their effectiveness. We compared patient-reported outcomes, revision rates, and mortality for the three most frequently
used brands within each prosthesis type: cemented (Exeter V40 Contemporary, Exeter V40 Duration and Exeter V40 Elite
Plus Ogee), cementless (Corail Pinnacle, Accolade Trident, and Taperloc Exceed), and hybrid (Exeter V40 Trilogy, Exeter V40
Trilogy, and CPT Trilogy).
Methods and Findings:We used three national databases of patients who had hip replacements between 2008 and 2011 in
the English NHS to compare functional outcome (Oxford Hip Score (OHS) ranging from 0 (worst) to 48 (best)) in 43,524
patients at six months. We analysed revisions and mortality in 187,201 patients. We used multiple regression to adjust for
pre-operative differences. Prosthesis type had an impact on post-operative OHS and revision rates (both p,0.001). Patients
with hybrid prostheses had the best functional outcome (mean OHS 39.4, 95%CI 39.1 to 39.7) and those with cemented
prostheses the worst (37.7, 37.3 to 38.1). Patients with cemented prostheses had the lowest reported 5-year revision rates
(1.3%, 1.2% to 1.4%) and those with cementless prostheses the highest (2.2%, 2.1% to 2.4%). Differences in mortality
according to prosthesis type were small and not significant (p = 0.06). Functional outcome varied according to brand among
cemented (p = 0.05, with Exeter V40 Duration having the best) and cementless prostheses (p = 0.01, with Corail Pinnacle
having the best). Revision rates varied according to brand among hybrids (p = 0.05, with Exeter V40 Trident having the
lowest).
Conclusions: Functional outcomes were better with cementless cups and revision rates were lower with cemented stems,
which underlies the good overall performance of hybrids. The hybrid Exeter V40 Trident seemed to produce the best overall
results. This brand should be considered as a benchmark in randomised trials.
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Introduction
Total hip replacement (THR) has proved to be a highly effective
intervention to alleviate pain and improve function in patients with
osteoarthritis. The basic technology, a metal stem inserted into the
femur and supporting a ball which articulates against a cup
inserted into the acetabulum, remains unchanged since its
introduction in routine clinical practice in the 1960s [1]. However,
cementless attachment for the metal stem, the cup or both
components has grown in popularity over fixation with cement
[2]. Prostheses with a cementless stem and cup are now the most
popular type in many countries [3–7].
Four types of prosthesis are being used: cemented (cemented
cup and stem), cementless (cementless cup and stem), hybrid
(cementless cup and cemented stem), and reverse hybrid
(cemented cup and cementless stem). Within each type, there
has been a proliferation of different brands (a brand is a distinct
combination of a stem and a cup produced by a specific
manufacturer). In 2011, 142 brands of femoral stems and 119
brands of acetabular cups were used in the UK [4]. However, the
ten most frequently used combinations of stem and cup brands
covered nearly half of all THRs undertaken.
Head-to-head randomised controlled trials comparing different
types and brands of hip prostheses are rare and trials that exist
include brands that have been superseded by newer designs [8].
Consequently, evidence on revision rates according to type and
brand comes from non-randomised cohort studies. A study
analysing the National Joint Registry of England and Wales
(NJR), the largest joint registry in the world, showed that cemented
prostheses have a lower revision rate than cementless prostheses
but it suggested at the same time an increased risk of mortality in
patients who had a cemented prosthesis [9]. A recent economic
analysis, also using NJR data, concluded that for most patients
hybrid prostheses are the most cost-effective option [10]. It found
that cementless prostheses are the most expensive but they do not
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provide sufficient improvement in health outcomes to justify their
additional costs.
The aim of this paper was to compare symptoms, function,
quality of life, revision rates and mortality after THR according to
prosthesis brand. We did not include reverse hybrid prostheses in
the analysis as this type was only used in about 2% of patients who
had a THR between 2003 and 2012 in England. We analysed data
collected for the National Patient Reported Outcome Measures
(PROMs) programme [11]. This programme aims to collect
patient characteristics and PROMs immediately before and six
months after surgery in all patients undergoing a hip replacement
funded by the English National Health Service (NHS). These
PROMs data were linked to the NJR and the Hospital Episode
Statistics (HES), the administrative database of all admissions to
English NHS hospitals [12].
Methods
Data sources
The NHS PROMs programme has included patients undergo-
ing a THR funded by the NHS since April 2009 [13]. Patients are
invited to complete a questionnaire immediately before surgery
and the recruitment rate was 78.8% in the year up to April 2011.
Six months after the surgery, a second questionnaire is sent to all
patients who completed a pre-operative questionnaire and the
response rate was 85.5% in the corresponding period [11].
The pre- and post-operative questionnaires include a generic
health-related quality-of-life measure (EQ-5D), and a condition
specific measure of symptoms and disability (Oxford Hip Score).
The EQ-5D comprises five questions each assessing a specific
dimension of health (mobility, self-care, usual activities, pain, and
anxiety and depression) with three response levels (‘‘no problems’’,
‘‘some or moderate problems’’, and ‘‘extreme problems’’) [14].
Responses are converted into a single score on a scale from 1
(perfect health), 0 (death), to 20.596 (worse than death with
extreme problems in all five dimensions) [15]. The Oxford Hip
Score assesses symptoms and function though 12 items with five
response levels. The item scores are summed to generate an overall
score that ranges from 0 (worst health status) to 48 (best health
status) [16]. The pre-operative questionnaire also asks patients
whether they had been told by a doctor that they had any of 12
common serious conditions [17]. The condition ‘‘arthritis’’ was not
considered in the analysis as in this study it is the primary disease
rather than a comorbid condition.
We obtained the PROMs records of all 178,723 patients who
had undergone a THR between April 2008 and June 2011 and
who had completed a pre-operative questionnaire. Of these,
108,474 records (60.7%) could be linked to the NJR and HES
based on a hierarchical deterministic linkage algorithm at the level
of individual patients [11]. This linkage was essential to determine
the diagnosis of the hip problem and the prosthesis brand. In
addition, it provided information about the patients’ socioeco-
nomic status that was derived from their postcode according to the
English Index of Multiple Deprivation (IMD) [18]. The IMD
ranks 32,482 areas, each of which covers an average population of
around 1500 people or 400 households. We grouped the patients
into five socioeconomic categories based on fifths of the national
ranking of these areas.
We excluded 17,161 patients who were younger than 55 or
older than 85 years old, 1589 who received a reverse hybrid
prosthesis, 1529 who had a resurfacing procedure, 6749 who had a
revision procedure, 4288 who did not have osteoarthritis as the
sole diagnosis of their hip problem, 164 who received bone-grafts,
3344 who had minimally invasive surgery, 4 who had a bilateral
procedure, 512 privately funded patients, 258 who had a revision
within a year of their primary operation, and 329 who died within
six months of the surgery. Of the remaining 72,547 patients, we
excluded a further 27,322 patients (37.7%) for whom the
prosthesis brand was unknown, and 1701 patients whose prosthesis
used a metal-on-metal or metal/ceramic combination bearing
surface. Of the 43,524 included patients, 16,882 had a cemented,
18,845 cementless, and 7797 a hybrid prosthesis. This ‘‘PROMs
data set’’ was used to determine quality of life after primary THR.
The NJR collects data on THRs undertaken in England and
Wales [19]. Case ascertainment has increased steadily since its
inception in 2003. Since 2007, more than 90% of all THRs are
being reported to the NJR. Unique patient identifiers allow linkage
of primary and revision procedures on the same patient. The data
include age, sex, the prosthesis components, American Society of
Anesthesiologists (ASA) grade [20], body mass index (BMI), type
of hospital (general hospital or specialist joint replacement centre),
seniority of operating surgeon (consultant [i.e senior surgeon] or
grade below consultant level), funding status of patient (NHS or
privately funded), date of revision of the THR, and date of death.
We received from the NJR all ‘‘linkable’’ records of patients
aged between 55 and 85 who were reported to have had a
unilateral primary THR with a diagnosis of osteoarthritis between
April 2003 and March 2012 funded by the NHS (n = 239,012).
Linkable records contain the patient’s NHS number, a unique
patient identifier used throughout the English NHS. The NHS
number was used by the NJR Centre to link all primary and
revision procedures relating to a single patient.
We excluded 5155 who received a reverse hybrid prosthesis,
14,255 who had a resurfacing procedure, 849 who had a revision
rather than a primary THR, 250 patients with missing data on
prostheses, 6250 who did not have osteoarthritis as the sole
diagnosis, 8329 who received bonegrafts, 5542 who had minimally
invasive surgery, and 11,181 who received a prosthesis in which at
least one of the bearing surfaces was metal. Of the 187,201
included patients, 91,966 had a cemented, 63,222 a cementless
and 32,013 a hybrid, THR. We used the Royal College of
Surgeons of England’s Charlson Score to determine the number of
comorbid conditions (0, 1, or 2 or more) that was captured in HES
records of hospital admissions in the year preceding the hip
replacement surgery related to 14 major conditions [21]. This
‘‘NJR data set’’ was used to determine revision rates and mortality.
We received all data from the Health and Social Care
Information Centre in an anonymised format. Given that these
data were previously collected in the course of normal care and
that the patients were not identifiable to the research team, review
by a Research Ethics Committee was not required.
Missing data
A post-operative PROM questionnaire was missing for 12.2%
of patients in the PROMs data set. Moreover, completed post-
operative questionnaires contained a small amount of missing or
incomplete data for the Oxford Hip Score (1.7%) and a larger
corresponding proportion for the EQ-5D (6.9%). To reduce the
risk of bias arising from missing PROMS data, we imputed missing
items using multiple imputation [22].
In the NJR data set, BMI was missing for 59.4% of patients.
Inspection of Kaplan-Meier curves of prosthesis revision rates
revealed a profile for patients with missing BMI very similar to
those with a BMI of less than 30 kg/m2. Consequently, patients
with missing BMI data were assumed to have a BMI less than 30.
Also, the number of comorbidities according to the Charlson
Score was not available for 31.4% of patients and for these patients
we added as a separate category.
Comparison of Hip Prosthesis Brands
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Comparisons
Patient-reported outcomes, revision rates and mortality were
compared according to the three most commonly used types
(cemented, cementless, and hybrid) and according to three most
commonly used brands within each type. The frequency with
which the types and brands were used was reported in patients
operated between April 2009 to June 2012 (cemented: Exeter V40
Contemporary, Exeter V40 Duration, Exeter V40 Elite plus Ogee;
cementless: Corail Pinnacle, Accolade Trident, Taperloc Exceed;
hybrid: Exeter V40 Trident, Exeter V40 Trilogy, CPT trilogy).
The cementless Furlong HAC CSF plus brand was more
frequently used (n= 7,531) than the Taperloc Exceed (n= 3,100).
There is however less than five years of follow-up data available for
the former and therefore it was not included in the comparison as
we would not be able to establish the 5-year revision rate.
Statistical analysis
Linear regression was used to adjust the comparison of post-
operative Oxford Hip Score and EQ-5D scores for age, sex, socio-
economic status, BMI, ASA grade, number of patient-reported
comorbidities, surgeon grade (consultant or not), and hospital type
(general or orthopaedic hospital) as well as the pre-operative
Oxford Hip Score and EQ-5D scores. Hip replacements of all
patients included in the PROMs data set were funded by the NHS
and therefore funding status was not included in this regression
model. Fractional polynomials were used to represent potential
non-linear relationships between the outcome and the factors
included in the regression model as continuous variables (age, pre-
operative Oxford Hip Score and EQ-5D, socio-economic status,
BMI, ASA grade, number of comorbidities) [23]. Overall
differences according to the three prosthesis types and according
to the three brands within each type were tested with Wald tests
and pairwise differences with t-tests.
Cox regression was use to compare revision rates according to
prosthesis type and brand with death treated as a censoring event.
Differences were expressed as hazard ratios (HR) which can be
considered as measures of relative risk. The hazard ratios were
adjusted for age, sex, BMI, ASA grade, surgeon grade, hospital
type, Charlson score and date of surgery. Overall differences as
well as pairwise differences in revision rates according to type and
brand were tested with likelihood ratio tests.
Cox regression was also used to compare mortality. We treated
revision as a censoring event, since revision operations carry a risk
of mortality and we wished to examine whether the primary
operation was linked to patient mortality irrespective of the
durability of the prosthesis. We adjusted for the same risk factors as
used in the comparison of revision rates.
Results are reported with 95% confidence intervals (CI). All
hazard ratios and reported p values are based on statistical tests
with adjustment for the specified pre-operative characteristics,
unless otherwise stated. P values less than 0.05 were considered to
indicate statistically significant differences. We did not adjust p
values for multiple comparisons. All analyses were undertaken in
Stata version 12 [24].
Results
Pre-operative characteristics
Patients who received a cemented prosthesis were on average
older and more likely to be female, to live in a socioeconomically
deprived area, to report at least two comorbidities, and to have an
ASA grade of 3 or higher than patients who received a cementless
prosthesis (Table 1). Also, patients with a cemented prosthesis were
likely before surgery to report more severe symptoms and disability
according to the Oxford Hip Score and a poorer quality of life
according to the EQ-5D than those with a cementless prosthesis.
Most of the characteristics of those receiving a hybrid lie in
between those of the cemented and cementless groups.
The pre-operative characteristics according to prosthesis brand
followed broadly the same pattern as observed for their type
(Table 2). A notable exception is that larger proportions of the
cemented Exeter V40 Contemporary, the cementless Corail
Pinnacle, and the hybrid Exeter V40 Trident were used in
orthopaedic hospitals compared to the other brands within their
respective type. Also, the hybrid CPT Trilogy was less often
implanted by consultant surgeons.
Table 1. Pre-operative characteristics of patients undergoing a primary hip replacement according to prosthesis type in the
PROMs data set.
Cemented Cementless Hybrid
Proportion of missing
data
No of patients 16,882 18,845 7,797
Mean (SD) age (years) 72.6 (6.7) 67.7 (7.2) 70.2 (7.2) 0
Women 35.4% 44.0% 38.4% 0
Socio-economic status:
in most deprived fifth 19.0% 18.8% 23.6% 1.2%
Two or more patient-reported comorbidities 26.3% 21.9% 24.0% 0
ASA grade 3 or higher 18.7% 12.3% 15.5% 0
Mean (SD) body mass index (kg/m2) 28.8 (5.2) 29.3 (5.4) 28.9 (5.4) 34.3%
Hip replacement
at specialist joint replacement centre 7.2% 10.4% 5.3% 0
by consultant, N(%) 81.6% 86.5% 80.7% 0
Pre-operative
mean (SD) Oxford Hip Score 17.3 (8.0) 18.2 (8.2) 18.2 (8.2) 0.7%
mean (SD) EQ-5D 0.33 (0.32) 0.36 (0.32) 0.35 (0.32) 5.5%
doi:10.1371/journal.pone.0073228.t001
Comparison of Hip Prosthesis Brands
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Post-operative function and quality of life
Post-operative Oxford Hip Scores and EQ-5D values varied
according to prosthesis type (overall p values ,0.001). Patients
who had received a hybrid prosthesis reported the best post-
operative function and quality of life (OHS=39.4, 95% CI 39.1 to
39.7; EQ-5D=0.80, 0.79 to 0.81) and patients who received a
cemented prosthesis the worst (OHS=37.7, 37.3 to 38.1; EQ-
5D=0.76, 0.75 to 0.77). Patients with a cementless prosthesis
reported intermediate outcomes (OHS=39.2, 38.8 to 39.5; EQ-
5D=0.79, 0.78 to 0.80).
Table 3 presents the post-operative Oxford Hip Scores and EQ-
5D values for the three most commonly used brands within each
prosthesis type. The Oxford Hip Scores varied according to brand
among the cementless prostheses after adjusting for pre-operative
differences (overall p value = 0.01). The Corail Pinnacle (the most
frequently used cementless brand) had Oxford HIip Scores which
were on average 0.5 higher than the Accolade Trident and
Taperloc Exceed (both pairwise p values ,0.05).
There is also some evidence for differences according to brand
among the cemented prostheses (overall p = 0.05). With adjust-
ment for pre-operative characteristics, the Oxford Hip Score for
the Exeter V40 Contemporary (the most frequently used cemented
brand) was on average 0.5 higher than for the Exeter V40 Elite
Plus Ogee (pairwise p value = 0.04) and 0.3 lower than for the
Exeter V40 Duration but the latter difference was not statistically
significant (pairwise p value = 0.4).
The Oxford Hip Scores among the three hybrid brands were
very similar and there was little evidence of a difference according
to brand (overall p = 0.7).
Within each of the three prosthesis types, the EQ-5D values
were similar across brands with adjusted differences of 0.01 or less
(Table 3). The overall p values within each of the three prosthesis
types were all 0.2 or higher.
Revision rates
Prosthesis type had a significant impact on 5-year revision rates
(overall p value ,0.001). The 5-year revision was lowest in
patients with a cemented prosthesis (1.28%, 95%CI 1.19% to
1.37%) and highest in those with a cementless prosthesis (2.23%,
2.08% to 2.39%). Patients with a hybrid prosthesis had a 5-year
revision rate (1.69%, 1.52% to 1.88%) that was in between those
with cemented or cementless prosthesis. Compared to patients
with a cemented prosthesis, the adjusted hazard ratios for revision
rates were 1.66 (1.51 to 1.83; pairwise p value ,0.001) for patients
with cementless prostheses, and 1.26 (1.12 to 1.42; pairwise p
value ,0.001) for patients with hybrid prostheses.
The differences in revision rates according to brand within the
three types were relatively small with slight evidence of differences
according to brand among the cemented (overall p value = 0.06),
cementless prostheses (overall p value 0.2), and hybrid prostheses
(overall p value = 0.05) if pre-operative characteristics were taken
into account. Within cemented prostheses, the Exeter V40
Duration had a revision rate that was higher than that of the
Exeter V40 Contemporary (hazard ratio 1.33; pairwise p
value = 0.03). Within the hybrid prostheses, the revision rate of
the CPT Trilogy was higher than that of the Exeter V40 Trident
(hazard ratio 1.56; pairwise p value = 0.02).
5-year mortality
Without adjustment for pre-operative characteristics, mortality
within the first five years after hip replacement differed
considerably according to prosthesis types. Mortality was highest
in patients with a cemented prosthesis (10.8%, 10.54% to 11.06%)
and lowest in those with a cementless prosthesis (6.9%, 6.6% to
7.2%; unadjusted hazard ratio 0.62, 0.60 to 0.65) with an
intermediate mortality result in patients with a hybrid prosthesis
(8.2%, 7.8% to 8.6%; unadjusted hazard ratio 0.73, 0.70 to 0.77)).
However, these differences were greatly reduced with adjustment
for pre-operative characteristics. Compared to patients who had a
cemented prosthesis, adjusted hazard ratios for mortality were
0.95 (0.91 to 1.00) with a cementless and 0.95 (0.90 to 1.00) with a
hybrid prosthesis (overall p value = 0.06). There was no statistical
significant difference in mortality according to brand within each
prosthesis type (overall p value = 0.7 within cemented, 0.7 within
cementless, and 0.2 within hybrid prostheses).
Discussion
Main findings
Our study demonstrates that patients who received a hybrid
prosthesis had the best functional outcomes and patients who
received a cemented prosthesis had the lowest revision rates.
Patients who had a cementless prosthesis had the highest revision
rates and intermediate patient-reported outcomes. Our analyses
according to brand identified the hybrid Exeter V40 Trident as
having lower revision rates than the other hybrid prostheses and
the cementless Corail Pinnacle as having better Oxford Hip Scores
than the other cementless prostheses.
The differences in mortality among patients who received
different types and brands of hip prosthesis were small. Adjustment
for pre-operative characteristics hugely decreased the observed
differences. We could only use age, sex, BMI, ASA grade and
hospital admission for comorbidity in preceding year to capture
potential differences in the patients’ pre-operative condition when
analysing mortality, and it is therefore likely that with a more
extensive characterisation of prognostic factors (e.g. nature and
severity of comorbidities), the mortality differences would have
fully disappeared.
Given these results, the hybrid Exeter V40 Trident prosthesis
produced the best overall results as it combined good post-
operative function and quality of life and low revision rates
compared to the other frequently used prosthesis brands.
However, this conclusion has to be interpreted with caution given
the statistical uncertainty in our estimates, the multitude of
comparisons that we carried out, and the potential residual bias.
Although our results may not be strong enough to guide directly
the choice of prosthesis brand for individual patients, we argue
that the hybrid Exeter V40 Trident should be considered as a yard
stick against which alternative clinical options should be
compared.
Strengths and limitations
This study is based on one of the world’s largest databases of
patient-reported outcomes and revision rates after hip replace-
ment[13,25]. Given their national coverage, the data represent
outcomes of routine practice rather than outcomes observed in
studies carried out only in specialist centres or within the context of
a clinical trial. Given the large size of this study, we were able to
detect small differences in post-operative function and quality of
life, revision rates and mortality. We could furthermore use
detailed information about the patients’ pre-operative character-
istics, either reported by the patients themselves or by their
clinicians, to adjust for differences in case mix.
We report a large number of statistical comparisons. As a result,
the probability of finding significant differences caused just by the
play of chance alone is increased. We decided against using a
formal procedure to adjust for multiple comparisons as we feel that
reporting the actual p values supports a truthful representation of
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the strength of the evidence. A further argument against
adjustment for multiple comparisons is that it is not obvious how
the number of comparisons should be counted [26]. Should we
adjust for the number of prosthesis brands within each prosthesis
type or for all brands considered? Should we also take into account
that we compared four different outcomes?
As mentioned earlier, residual confounding cannot be fully
ruled out although its impact on the results of comparing
prosthesis brands within type is likely to be relatively small. The
pre-operative case mix profiles according to brand within type
were rather similar which suggests that the impact of unknown
confounding would be limited.
We report functional outcomes measured at six months after
surgery. A recently published study on symptoms and disability
over a 5-year period following THR found substantial improve-
ment in the first year and on average stable outcomes after the first
year [27] which suggest that the differences in symptoms and
disability between prosthesis types and brands reported in this
study will be sustained for at least the first five years.
The revisions were identified by linking hip replacement
procedures carried out on the same hip within the NJR. Additional
work carried out by the NJR Centre has demonstrated that
between 30% to 50% of revisions may have gone undetected by
the NJR between 2003 and 2009 [28,29]. However, detailed
analyses of the pattern of underdetection have demonstrated that
there is no apparent clustering within individual surgeons or
hospitals [29], which suggests that it is also independent of
prosthesis type and brand. If that is the case, then incomplete
detection of revisions only affected the precision and not the
accuracy of the relative differences in reported revision rates.
The extent of underdetection of revisions may have gradually
decreased as a result of improving patient recruitment rates and a
more complete recording of patient identifiers [29]. We have
therefore included date of surgery in the regression model that was
used for risk adjustment to minimise bias potentially linked to
changes over time in the frequencies of use of prosthesis types and
brands.
Comparison with other studies
Our revision rates according to brand follow largely the revision
rates published in the 9th NJR Annual Report [29]. However, a
crucial difference between the results published by the NJR Centre
and ours is that we have excluded patients who had a prosthesis
with metal-on-metal bearing surfaces. They were excluded
because it has been suggested that the use of metal-on-metal
bearing surfaces could explain the higher revision rates of
cementless prostheses [30]. However, even with these patients
being excluded, the higher revision rates of cementless brands
remained, demonstrating that the metal-on-metal bearing surface
is an unlikely explanation.
A study based on the New Zealand Joint Registry found that
patients with poorer Oxford Hip Scores at six months have a
higher risk of revision in the next five years [31]. It is important to
note that the differences in functional outcome and revision rates
that we observed between prosthesis types do not follow the same
pattern. Cementless prosthesis brands had the best functional
outcomes at six months but also the highest revision rates at five
years which suggests that the determinants of functional outcome
and revision rates do not fully overlap.
It has been suggested based on an analysis of NJR data that
there is ‘‘a small but significantly increased risk of death with
cemented procedures’’ [9]. That analysis found that mortality after
a hip replacement with cementless hip prostheses was 10% lower
than with cemented prostheses. The authors suggested that
cementation could drive emboli into the circulation which can
lead to respiratory problems. However, a number of responses to
this paper pointed to selection bias as the most likely explanation
for the observed effect on mortality [32–34]. In our analysis, we
adjusted not only for age, sex and ASA score but also for BMI,
number of comorbidities year of surgery and found that the
apparent impact of the use of cement was further reduced. For
that reason, it is likely that with an even more complete adjustment
for pre-operative case mix differences the mortality differences
according to prosthesis type will vanish.
A further argument against cementation as a cause for an
increase in mortality in patients with cemented prostheses is that
we did not find an increased mortality in patients with hybrid
prostheses, in which cementation is used to fix the stem of this
prosthesis type to the femoral bone.
Further implications
The differences in outcomes after hip replacement according to
prosthesis type are considerably larger than the difference
according brand within each type. Post-operative function and
quality of life is better with a cementless cup (i.e. patients with
cementless or hybrid prostheses) whereas revision rates are lower
with a cemented stem (i.e. patients with cemented or hybrid
prostheses) which underlines the good overall performance of the
hybrid brands.
Our results demonstrate the importance of linking patient-
reported outcomes with data on revisions after hip replacement.
Linkage with general practice records might provide further data
on physical activity, smoking and alcohol use which would allow
more complete adjustment for the impact of these case-mix
difference. In addition, a national resource of linked data provides
a structure within which future randomised controlled trials can be
carried out efficiently measuring patient-reported outcomes as well
as revision rates. Our non-randomised study demonstrates that the
hybrid Exeter V40 Trident should be used as a benchmark against
which other brands should be tested. The results of these trials
should be used in economic analyses to explore the tradeoffs
between different outcomes and to estimate quality-adjusted life
years and costs.
Acknowledgments
Professor Paul Gregg, consultant orthopaedic surgeon, James Cook
Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough,
UK and Vice-Chair, Steering Committee, National Joint Registry for
England and Wales, provided clinical input and commented on earlier
drafts of the manuscript.
Author Contributions
Conceived and designed the experiments: MP RG NB JM. Analyzed the
data: MP. Wrote the paper: MP JM. Commented on and revised drafts:
MP RG NB JM.
References
1. Learmouth ID, Young C, Rorabeck C (2007) The operation of the century: total
hip replacement. Lancet 370: 1508–1519.
2. Yamada H, Yoshihara Y, Henmi O, Morita M, Shiromoto Y, et al. (2009)
Cementless total hip replacement: past, present, and future. J Orthop Sci 14:
228–241.
Comparison of Hip Prosthesis Brands
PLOS ONE | www.plosone.org 7 September 2013 | Volume 8 | Issue 9 | e73228
3. Canadian Joint replacement Registry (2009) Hip and Knee replacements in
Canada - 2008–2009 Annual Report. Ottawa, Ontario: Canadian Institute for
Health Information. Available: https://secure.cihi.ca/free_products/2008_cjrr_
annual_report_en.pdf. Accessed 30 July 2013.
4. National Joint Registry for England and Wales (2011) 8th Annual Report.
National Joint Registry for England and Wales. Available: http://www.njrcentre.
org.uk/njrcentre/portals/0/documents/NJR%208th%20annual%20report%202011.
Pdf. Accessed 30 July 2013.
5. Graves S, Davidson D, de Steiger R, Tomkins A, Ryan P, et al. (2011) Australian
Orthopaedic Association Nattional Joint Replacement Registry. Annual Report.
Adelaide: Australian Orthopaedic Assocation. Available: https://aoanjrr.dmac.
adelaide.edu.au/documents/10180/44800/Annual%20Report%202011?version=1.
2&t=1347337258367. Accessed 30 July 2013.
6. Mendenhall S (2004) 2003 Hip and knee implant review. Orthopedic News
Network 14: 1–16.
7. Stea S, Bordini B, De Clerico M, Petropulacos K, Toni A (2009) First hip
arthroplasty register in Italy: 55,000 cases and 7 year follow-up. Int Orthop 33:
339–346.
8. Laupacis A, Bourne R, Rorabeck C, Feeny D, Tugwell P, et al. (2002)
Comparison of total hip arthroplasty performed with and without cement. A
randomized trial. J Bone Joint Surg Am 84: 1823–1828.
9. McMinn DJW, Snell KIE, Daniel J, Treacy RBC, Pynsent PB, et al. (2012)
Mortality and implant revision rates of hip arthroplasty in patients with
osteoarthritis: registry based cohort study. BMJ 344: e3319.
10. Pennington M, Grieve R, Sekhon JS, Gregg P, Black N, et al. (2013) Cemented,
cementless and hybrid prostheses for total hip replacement: a cost-effectiveness
analysis. BMJ 346: f1026.
11. Health and Social Care Information Centre (2010) Provisional Monthly Patient
Reported Outcome Measures (PROMs) in England: April 2009 - April 2010:
Available: http://www.hscic.gov.uk/catalogue/PUB10653. Accessed 30 July
2013.
12. Health and Social Care Information Centre (2013) Hospital Episode Statistics.
Available: http://www.hscic.gov.uk/hes. Accessed 30 July 2013.
13. Ousey K, Cook L (2011) Understanding patient reported outcome measures
(PROMs). Br J Community Nurs 16: 80–82.
14. The EuroQol Group (1990) EuroQol--a new facility for the measurement of
health-related quality of life. Health Policy 16: 199–208.
15. Dolan P, Gudex C, Kind P, Williams A (1994) The measurement and valuation
of health. First report on the main survey. University of York. Available: http://
www.york.ac.uk/media/che/documents/reports/MVH%20First%20Report.
pdf. Accessed 30 July 2013.
16. Dawson J, Fitzpatrick R, Carr A, Murray D (1996) Questionnaire on the
perceptions of patients about total hip replacement. J Bone Joint Surg Br 78:
185–190.
17. Chard J, Kuczawski M, van der Meulen J (2011) Outcomes of elective surgery
undertaken in independent sector treatment centres and HNS provider in
England. BMJ 343:d6404.
18. Noble M, Mclennan D, Wilkinson K, Whitworth A, Exley S, et al. (2007) The
English Indices of Deprivation 2007. Department of Communities and Local
Government. http://www.sheffield.ac.uk/polopoly_fs/1.282375!/file/
IMD2007.pdf. Accessed 30 July 2013.
19. National Joint Registry for England and Wales (2013) About the NJR.
Available: http://www.njrcentre.org.uk/njrcentre/AbouttheNJR/tabid/73/
Default.aspx. Accessed 30 July 2013.
20. American Society of Anesthesiologists Physical Status Classification System.
ASA Physical Status Classification System. Available http://www.asahq.org/
Home/For-Members/Clinical-Information/ASA-Physical-Status-Classification-
System. Accessed 30 July 2013.
21. Armitage JN, van der Meulen JH, Royal College of Surgeons Co-morbidity
Consensus Group (2010) Identifying comorbidity in surgical patients using
administrative data. Br J Surg 97: 772–81.
22. Rubin DB (2004) Multiple imputation for nonresponse in surveys. New York:
John Wiley and sons.
23. Sauerbrei W, Royston P (1999) Building multivariable prognostic and diagnostic
models: Transformation of the predictors by using fractional polynomials.
J R Statist Soc A 162: 71–94.
24. Stata version 12 (2011) StataCorp LP: 4905 Lakeway Drive, College Station,
Texas, USA. Available http://www.stata.com/stata12/. Accessed 30 July 2013.
25. Health Care Quality Improvement Partnership (2010) NJR adds one millionth
record to database and announces abmitious plans for 2011. Available http://
www.hqip.org.uk/njr-adds-one-millionth-record-to-database-and-announces-
plans-for-201/. Accessed 30 July 2013.
26. Perneger TV (1998) What’s wrong with Bonferroni adjustments. BMJ 316:
1236–1238.
27. Judge A, Arden NK, Batra RN, Thomas G, Beard D, et al (2013) The
association of patient characteristics and surgical variables on symptoms of pain
and function over 5 years following primary hip-replacement surgery: a
prospective cohort study. BMJ Open 3: e002453.
28. National Joint Registry for England and Wales (2010) 7th Annual Report.
National Joint Registry for England and Wales. Available: http://www.
njrcentre.org.uk/njrcentre/portals/0/njr%207th%20annual%20report%202010.
pdf. Accessed 30 July 2013.
29. National Joint Registry for England and Wales (2012) 9th Annual Report.
National Joint Registry for England and Wales. Available: http://www.
njrcentre.org.uk/njrcentre/Portals/0/Documents/England/Reports/9th_
annual_report/NJR%209th%20Annual%20Report%202012.pdf. Accessed 30
July 2013.
30. Smith AJ, Dieppe P, Vernon K, Porter M, Blom AW, et al (2012) Failure rates of
stemmed metal-on-metal hip replacements: analysis of data from the National
Joint Registry of England and Wales. Lancet 379: 1199–1204.
31. Rothwell AG, Hooper GJ, Hobbs A, Frampton CM (2010) An analysis of the
Oxford hip and knee scores and their relationship to early joint revision in the
New Zealand Joint Registry. J Bone Joint Surg Br 92: 413–8.
32. Breusch SJ, Howie CR (2012) Excess mortality can be explained by case mix
selection. BMJ 345: e7137.
33. Dalgleish S, Finlayson D (2012) Caution is needed in interpreting results. BMJ
345: e7144.
34. Jameson SS, Baker P, Deehan D, Reed M, Mason J (2012) Paper’s conclusions
will only cause confusion. BMJ 345: e7005.
Comparison of Hip Prosthesis Brands
PLOS ONE | www.plosone.org 8 September 2013 | Volume 8 | Issue 9 | e73228
